• Other
  • Current

CODA Biotherapeutics is developing a novel chemogenetic platform to modulate neuronal activity. In the CODA approach, viral vectors directly administered to target neurons deliver engineered neurotransmitter receptors that respond exclusively to non-native safe, orally bio-available drugs. Drug is then administered to activate or silence the targeted neurons, depending on the receptor used. The approach will be used to treat neuropathic pain, epilepsy, movement disorders and other severe nervous system disorders.